This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Oct 2012

Oncologists take 'wait-and-see' approach to biosimilar monoclonal antibodies

US oncologists are taking a cautious approach to prescribing biosimilar versions of monoclonal antibodies.


Adoption of biosimilar versions of erythropoiesis-stimulating agents (ESAs) and G-CSFs is expected to be rapid among US oncologists, but the same is unlikely to be true for biosimilar monoclonal antibodies, a survey suggests.

Related News